Phase III Study Shows Novartis Drug Afinitor® More Than Doubles Time Without ... - PR Newswire (press release) Print
PR Newswire (press release)Afinitor is approved for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib(4).

... read more